Physician profile
Shaguna Mathur
NPI 1225470396
$1,174.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $181 · 2021: $232 · 2022: $23.66 · 2023: $477 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $207.69 | 2019-2020 | |
| Neurelis, INC. | $196.68 | 2023-2024 | Valtoco |
| Biogen, INC. | $133.43 | 2020-2023 | Spinraza, Spinraza |
| Biohaven Pharmaceuticals, INC. | $123.90 | 2021 | |
| Immedica Pharma US, INC. | $110.07 | 2023 | |
| Ns Pharma, INC. | $99.41 | 2021-2023 | Viltepso |
| Takeda Pharmaceuticals U.S.A., INC. | $74.35 | 2023 | Elaprase, Vpriv |
| Genentech USA, INC. | $58.96 | 2021-2023 | Evrysdi |
| Biocodex, INC. | $41.25 | 2024 | |
| Jazz Pharmaceuticals INC. | $35.56 | 2023-2024 | |
| Biomarin Pharmaceutical INC. | $26.24 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $23.07 | 2024 | |
| Acadia Pharmaceuticals INC | $16.77 | 2024 | Daybue |
| Livanova USA, INC. | $15.09 | 2019 | |
| Medtronic USA, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaguna Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.